Imeglimin may improve albuminuria associated with partial suppression of inflammatory and fibrotic markers in diabetic kidney disease
Open Access
- 15 September 2026
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1895272
Abstract
Imeglimin is an oral hypoglycemic agent marketed in Japan that has shown glucose-lowering effects in Japanese patients with type 2 diabetes in TIMES trials. However, it is not well known whether imeglimin can affect diabetic kidney disease (DKD). To clarify this, we investigated the potential association between the effects of imeglimin and DKD using diabetic mice (DM) and cultured endothelial cells. Administration of imeglimin significantly lowered urinary albumin excretion in DKD but did not significantly affect blood glucose and glycated albumin. RNA sequencing analysis of the renal cortex indicated the upregulation of antioxidant, oxidative phosphorylation, and AMP-activated protein kinase (AMPK) signaling pathways and downregulation of inflammation, atherosclerosis, and reactive oxygen species. Additionally, imeglimin decreased the mRNA expression of TNF-α , F4/80 , and fibronectin in the renal cortex of mice with DKD. In parallel with the findings that imeglimin reduced the protein expression of fibronectin in the renal cortex of mice with DKD, renal histological fibrosis was significantly increased in diabetic mice compared with non-diabetic mice (NDM), which was significantly reduced in mice receiving imeglimin. In an in vitro study, high glucose (HG) induced the mRNA expression of Nlrp3 , Vcam-1 , and NOX4 , which were downregulated by imeglimin. These results suggest that imeglimin could improve albuminuria by partially suppressing inflammatory and fibrotic markers in DKD.Keywords
This publication has 40 references indexed in Scilit:
- Exploring new mechanisms of Imeglimin in diabetes treatment: Amelioration of mitochondrial dysfunctionBiomedicine & Pharmacotherapy, 2024
- Improving the Effects of Imeglimin on Endothelial Function: A Prospective, Single-Center, Observational StudyDiabetes Therapy, 2023
- Targeting inflammation to treat diabetic kidney disease: the road to 2030Kidney International, 2022
- Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivityEndocrinology, Diabetes & Metabolism, 2022
- Molecular mechanisms and therapeutic targets for diabetic kidney diseaseKidney International, 2022
- Imeglimin Hydrochloride: First ApprovalDrugs, 2021
- The mechanism by which imeglimin inhibits gluconeogenesis in rat liver cellsEndocrinology, Diabetes & Metabolism, 2021
- Lessons learned from two randomized controlled trials: CITIES and STOP-DKDContemporary Clinical Trials Communications, 2020
- Short‐and long‐term administration of imeglimin counters cardiorenal dysfunction in a rat model of metabolic syndromeEndocrinology, Diabetes & Metabolism, 2020
- IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040Diabetes Research and Clinical Practice, 2017